Most notably, the Epstein–Barr virus (EBV) DNA copy number, which is correlated with NPC burden12, showed a robust decline after the combination treatment but not after PD-1 treatment alone (Fig. 1h), indicating that the combination therapy effectively altered T cell activation and suppressed tumour progression. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.